Fortis Healthcare Strengthens Hold in Agilus Diagnostics with ₹429 Crore IFC Deal

Fortis Healthcare's newest move has reportedly been to increase the stake in Agilus Diagnostics, formerly SRL Diagnostics, reinforcing its hold in the diagnostics space. This was a collaboration with the International Finance Corporation (IFC) for a deal valued at Rs 429 crore. This investment marks Fortis's clear intent to expand its footprints in diagnostics services- which forms a crucial part of the ecosystem of healthcare.  

Agilus Diagnostics is a leading player offering various pathology and radiology procedures. It works hand in hand with an extensive network across the country intending to create a quality solution in diagnostics. Furthermore, this acquisition is expected to strengthen the existing business and improve the utilization of technology for Agilus. Last but not least, it would also pioneer Agilus's future expansion plans to other geographic locations.  

IFC, an organizational unit of the World Bank Group, refers to a global institution dedicated to enhancing growth in the private sector in emerging economies on a sustainable basis. The collaboration further generates confidence regarding India's healthcare potential and the demand for high quality diagnostics in ever-increasing numbers.  

And then Fortis strengthens the thrust for therapeutic services as well as foraged to offer its strong transnational presence in the field of healthcare into its referential leadership position. The deal, as they put it, dovetails into the Forts strategy of developing the diversified portfolio that strengthens its integrated health care model, which spans hospitals, diagnostics, and related services.